Literature DB >> 18331465

Probiotic Lactobacillus reuteri promotes TNF-induced apoptosis in human myeloid leukemia-derived cells by modulation of NF-kappaB and MAPK signalling.

Chandra Iyer1, Astrid Kosters, Gautam Sethi, Ajaikumar B Kunnumakkara, Bharat B Aggarwal, James Versalovic.   

Abstract

The molecular mechanisms of pro-apoptotic effects of human-derived Lactobacillus reuteri ATCC PTA 6475 were investigated in this study. L. reuteri secretes factors that potentiate apoptosis in myeloid leukemia-derived cells induced by tumour necrosis factor (TNF), as indicated by intracellular esterase activity, terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labelling assays and poly (ADP-ribose) polymerase cleavage. L. reuteri downregulated nuclear factor-kappaB (NF-kappaB)-dependent gene products that mediate cell proliferation (Cox-2, cyclin D1) and cell survival (Bcl-2, Bcl-xL). L. reuteri suppressed TNF-induced NF-kappaB activation, including NF-kappaB-dependent reporter gene expression in a dose-and time-dependent manner. L. reuteri stabilized degradation of IkappaBalpha and inhibited nuclear translocation of p65 (RelA). Although phosphorylation of IkappaBalpha was not affected, subsequent polyubiquitination necessary for regulated IkappaBalpha degradation was abrogated by L. reuteri. In addition, L. reuteri promoted apoptosis by enhancing mitogen-activated protein kinase (MAPK) activities including c-Jun N-terminal kinase and p38 MAPK. In contrast, L. reuteri suppressed extracellular signal-regulated kinases 1/2 in TNF-activated myeloid cells. L. reuteri may regulate cell proliferation by promoting apoptosis of activated immune cells via inhibition of IkappaBalpha ubiquitination and enhancing pro-apoptotic MAPK signalling. An improved understanding of L. reuteri-mediated effects on apoptotic signalling pathways may facilitate development of future probiotics-based regimens for prevention of colorectal cancer and inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18331465     DOI: 10.1111/j.1462-5822.2008.01137.x

Source DB:  PubMed          Journal:  Cell Microbiol        ISSN: 1462-5814            Impact factor:   3.715


  62 in total

Review 1.  Probiotics, enteric and diarrheal diseases, and global health.

Authors:  Geoffrey A Preidis; Colin Hill; Richard L Guerrant; B S Ramakrishna; Gerald W Tannock; James Versalovic
Journal:  Gastroenterology       Date:  2010-11-12       Impact factor: 22.682

2.  Probiotics and Gastrointestinal Disease: Clinical Evidence and Basic Science.

Authors:  Elaine O Petrof
Journal:  Antiinflamm Antiallergy Agents Med Chem       Date:  2009-09-01

Review 3.  Disruption of NF-kappaB signalling by ancient microbial molecules: novel therapies of the future?

Authors:  Fang Yan; D Brent Polk
Journal:  Gut       Date:  2010-04       Impact factor: 23.059

Review 4.  Microbes in gastrointestinal health and disease.

Authors:  Andrew S Neish
Journal:  Gastroenterology       Date:  2008-11-19       Impact factor: 22.682

5.  Probiotics improve outcomes after Roux-en-Y gastric bypass surgery: a prospective randomized trial.

Authors:  Gavitt A Woodard; Betsy Encarnacion; John R Downey; Joseph Peraza; Karen Chong; Tina Hernandez-Boussard; John M Morton
Journal:  J Gastrointest Surg       Date:  2009-04-18       Impact factor: 3.452

6.  The effects of probiotic bacteria on glycaemic control in overweight men and women: a randomised controlled trial.

Authors:  K L Ivey; J M Hodgson; D A Kerr; J R Lewis; P L Thompson; R L Prince
Journal:  Eur J Clin Nutr       Date:  2014-02-26       Impact factor: 4.016

Review 7.  Probiotics-host communication: Modulation of signaling pathways in the intestine.

Authors:  Carissa M Thomas; James Versalovic
Journal:  Gut Microbes       Date:  2010 May-Jun

Review 8.  Reactive oxygen production induced by the gut microbiota: pharmacotherapeutic implications.

Authors:  R M Jones; J W Mercante; A S Neish
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

9.  The human microbiome and probiotics: implications for pediatrics.

Authors:  Michael H Hsieh; James Versalovic
Journal:  Curr Probl Pediatr Adolesc Health Care       Date:  2008 Nov-Dec

Review 10.  Probiotics: progress toward novel therapies for intestinal diseases.

Authors:  Fang Yan; David Brent Polk
Journal:  Curr Opin Gastroenterol       Date:  2010-03       Impact factor: 3.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.